AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

AstraZeneca Says Calquence/Chemo Combo Data Shows Additional 16.8 Months Without Disease Progression In Patients With Certain Type Of Blood Cancer. by Vandana Singh Benzinga Editor.

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...

FDA fully approves AstraZeneca's Calquence combo therapy, reducing MCL progression/death risk by 27% in Phase 3 ECHO trial. Median progression-free survival extended to 66.4 months with Calquence ...

ASH: AstraZeneca proposes fixed-duration Calquence combos in chronic lymphocytic leukemia By Angus Liu Dec 8, 2024 11:00am AstraZeneca ASH 2024 Calquence chronic lymphocytic leukemia ...

WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the AMPLIFY Phase III trial showed AstraZeneca’s CALQUENCE ® (acalabrutinib) in combination with venetoclax demonstrated a statistically ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

AstraZeneca AZN announced that the FDA has accepted the supplemental new drug application (sNDA), seeking approval for the expanded use of Calquence (acalabrutinib) in mantle cell lymphoma (MCL).

AstraZeneca has received another boost to its aspirations in oncology with the FDA approval of Calquence, a next generation treatment for mantle cell lymphoma (MCL). Calquence (acalabrutinib) is ...